Abstract
Heart failure (HF) represents a complex multifactorial syndrome, characterized by crucial structural and functional abnormalities of the myocardium. Matrix metalloproteinases are associated with left ventricular dysfunction, adverse left ventricular remodelling and prognosis after acute myocardial infarction. There is a strong association between oxidative stress and MMPs in the pathophysiology of HF. As MMPs are strongly associated to the pathogenesis and pathophysiology of HF, several agents have been proposed as potential modulators of these molecules. Classical agents such as statins, angiotensin converting enzyme inhibitors (ACEIS) and beta-blockers and a variety of novel agents have been implicated in the pathogenesis and progression of heart failure via the matrix metalloproteinases pathway and consist of possible future therapeutic targets.
Keywords: Clinical implications, dysfunction, heart failure, left ventricle remodeling, matrix metalloproteinases, multifactorial syndrome, oxidative stress, crucial structural, myocardium, ventricular dysfunction, pathophysiology, ventricular remodelling, therapeutic targets, enzyme inhibitors
Current Topics in Medicinal Chemistry
Title:Matrix Metallopropteinases in Heart Failure
Volume: 12 Issue: 10
Author(s): Dimitris Tousoulis, Anna-Maria Kampoli, Nikolaos Papageorgiou, Charalambos Antoniades, Gerasimos Siasos, George Latsios, Eleftherios Tsiamis and Christodoulos Stefanadis
Affiliation:
Keywords: Clinical implications, dysfunction, heart failure, left ventricle remodeling, matrix metalloproteinases, multifactorial syndrome, oxidative stress, crucial structural, myocardium, ventricular dysfunction, pathophysiology, ventricular remodelling, therapeutic targets, enzyme inhibitors
Abstract: Heart failure (HF) represents a complex multifactorial syndrome, characterized by crucial structural and functional abnormalities of the myocardium. Matrix metalloproteinases are associated with left ventricular dysfunction, adverse left ventricular remodelling and prognosis after acute myocardial infarction. There is a strong association between oxidative stress and MMPs in the pathophysiology of HF. As MMPs are strongly associated to the pathogenesis and pathophysiology of HF, several agents have been proposed as potential modulators of these molecules. Classical agents such as statins, angiotensin converting enzyme inhibitors (ACEIS) and beta-blockers and a variety of novel agents have been implicated in the pathogenesis and progression of heart failure via the matrix metalloproteinases pathway and consist of possible future therapeutic targets.
Export Options
About this article
Cite this article as:
Tousoulis Dimitris, Kampoli Anna-Maria, Papageorgiou Nikolaos, Antoniades Charalambos, Siasos Gerasimos, Latsios George, Tsiamis Eleftherios and Stefanadis Christodoulos, Matrix Metallopropteinases in Heart Failure, Current Topics in Medicinal Chemistry 2012; 12 (10) . https://dx.doi.org/10.2174/1568026611208011181
DOI https://dx.doi.org/10.2174/1568026611208011181 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bivalirudin or Heparin Treatment During Transcatheter Valve Interventions: Where are we Now?
Current Pharmaceutical Design The Chromogranin A-Derived Vasostatins: New Players in the Endocrine Heart
Current Medicinal Chemistry Therapeutic Interventions in the Glyc(oxid)ation Pathway
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Hypertension and Cardiovascular Risk: The Importance of a Global Approach to Risk Management in the Light of Current Hypertension Guidelines
Current Hypertension Reviews General Aspects of Metal Toxicity
Current Medicinal Chemistry Hydrogen Sulfide: From Physiology to Pharmacology
Inflammation & Allergy - Drug Targets (Discontinued) Targeting the Toll-System in Cardiovascular Sciences
Recent Patents on Inflammation & Allergy Drug Discovery Some Peculiar Effects of NO-Synthase Inhibition on the Structure and Function of Cardiovascular System
Current Pharmaceutical Biotechnology Role of the Dopamine Transporter in the Action of Psychostimulants, Nicotine, and Other Drugs of Abuse
CNS & Neurological Disorders - Drug Targets Exercise-induced Physiological Hypertrophy: Insights from Genomics
Current Genomics Myocardial Energy Substrate Metabolism in Heart Failure : from Pathways to Therapeutic Targets
Current Pharmaceutical Design Mechanisms of Salt-Sensitive Hypertension
Current Hypertension Reviews Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) Vasculopathy in Hyperthyroid Rats and Targets for Drug Effects
Vascular Disease Prevention (Discontinued) Brachial-Ankle Pulse Wave Velocity in the Measurement of Arterial Stiffness: Recent Evidence and Clinical Applications
Current Hypertension Reviews Cardiovascular Effects of Losartan and Its Relevant Clinical Application
Current Medicinal Chemistry Chromogranin A and the Endothelial Barrier Function
Current Medicinal Chemistry High-output Cardiac Failure: A Forgotten Phenotype in Clinical Practice
Current Cardiology Reviews Statins Therapy may Change a Course of Lung Fibrosis and Pulmonary Hypertension: A New Indication for Therapy or Just “Statinomania”?
Current Respiratory Medicine Reviews Brain Structural Effects of Psychopharmacological Treatment in Bipolar Disorder
Current Neuropharmacology